ACM
TMO icon

Atlanta Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Atlanta Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$407M Buy
802,260
+42,797
+6% +$24M 1.81% 9
2022
Q2 		$413M Sell
759,463
-54,807
-7% -$30.2M 1.78% 8
2022
Q1 		$481M Buy
814,270
+4,051
+0.5% +$2.33M 1.78% 8
2021
Q4 		$541M Sell
810,219
-20,647
-2% -$12.9M 1.83% 6
2021
Q3 		$475M Sell
830,866
-91,930
-10% -$50.5M 1.7% 8
2021
Q2 		$466M Buy
922,796
+5,864
+0.6% +$2.77M 1.61% 11
2021
Q1 		$418M Sell
916,932
-85,047
-8% -$40.6M 1.48% 15
2020
Q4 		$467M Sell
1,001,979
-49,177
-5% -$23.1M 1.67% 9
2020
Q3 		$464M Sell
1,051,156
-65,365
-6% -$27M 1.91% 3
2020
Q2 		$405M Buy
1,116,521
+61,446
+6% +$20.6M 1.71% 7
2020
Q1 		$299M Buy
1,055,075
+67,099
+7% +$21.2M 1.56% 10
2019
Q4 		$321M Buy
987,976
+80,051
+9% +$24.3M 1.33% 21
2019
Q3 		$264M Buy
907,925
+79,945
+10% +$22.9M 1.15% 26
2019
Q2 		$243M Buy
827,980
+15,849
+2% +$4.37M 1.09% 29
2019
Q1 		$222M Buy
812,131
+19,676
+2% +$4.9M 1.06% 33
2018
Q4 		$177M Sell
792,455
-56,571
-7% -$13.3M 0.98% 36
2018
Q3 		$207M Sell
849,026
-38,154
-4% -$8.78M 0.96% 41
2018
Q2 		$184M Sell
887,180
-22,685
-2% -$4.82M 0.92% 41
2018
Q1 		$188M Sell
909,865
-6,791
-0.7% -$1.43M 0.97% 40
2017
Q4 		$174M Sell
916,656
-59,622
-6% -$11.4M 0.91% 42
2017
Q3 		$185M Sell
976,278
-35,151
-3% -$6.37M 1.05% 38
2017
Q2 		$176M Sell
1,011,429
-22,873
-2% -$3.84M 1.03% 40
2017
Q1 		$159M Buy
1,034,302
+137,350
+15% +$21M 0.98% 38
2016
Q4 		$127M Buy
896,952
+91,531
+11% +$13.5M 0.81% 46
2016
Q3 		$128M Buy
805,421
+75,394
+10% +$11.6M 0.85% 44
2016
Q2 		$108M Buy
730,027
+33,265
+5% +$4.91M 0.72% 53
2016
Q1 		$98.7M Sell
696,762
-5,788
-0.8% -$776K 0.7% 50
2015
Q4 		$99.7M Buy
702,550
+370,080
+111% +$49.4M 0.73% 52
2015
Q3 		$40.7M Buy
+332,470
New +$43.3M 0.31% 96

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atlanta Capital Management's TMO Position: Q3 2022 in Review

Atlanta Capital Management increased its Thermo Fisher Scientific (TMO) stake by 5.6% in Q3 2022, buying an estimated $24M and bringing the position to 802,260 shares worth $407M. The position accounts for 1.81% of the portfolio, ranked #9.

Atlanta Capital Management first reported a position in TMO in Q3 2015 and has held it in 29 quarters since. The position peaked at $541M in Q4 2021. 2,268 funds tracked by Wall St. Rank hold TMO as of Q3 2022.

  • Atlanta Capital Management held 802,260 shares of Thermo Fisher Scientific worth $407M as of Q3 2022.
  • Atlanta Capital Management bought 42,797 Thermo Fisher Scientific shares in Q3 2022, an estimated $24M.
  • Thermo Fisher Scientific made up 1.81% of Atlanta Capital Management's portfolio in Q3 2022, its #9 holding.
  • Atlanta Capital Management first reported a position in Thermo Fisher Scientific in Q3 2015 and has held it in 29 quarters since.
  • Atlanta Capital Management's Thermo Fisher Scientific position peaked at $541M in Q4 2021.
  • 2,268 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2022.

Based on Atlanta Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.